Ironwood Pharmaceuticals (IRWD) Research & Development (2010 - 2026)

Ironwood Pharmaceuticals has disclosed Research & Development across 17 years of filings, most recently posting $21.9 million for Q1 2026.

• Research & Development for Q1 2026 came in at $21.9 million, down 20.02% year-over-year; the trailing twelve-month figure through Mar 2026 was $89.6 million (down 20.7% YoY), and the FY2025 annual result was $95.1 million, down 14.62% from the prior year.
• Research & Development came in at $21.9 million for Q1 2026 at Ironwood Pharmaceuticals, roughly flat from $21.9 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $35.7 million in Q4 2023 to a low of $6.0 million in Q2 2023.
• The 5-year median for Research & Development is $22.5 million (2025), against an average of $21.2 million.
• Across the five-year window, Research & Development plunged 67.2% in 2022 and soared 406.47% in 2024, its largest moves.
• Ironwood Pharmaceuticals' Research & Development stood at $10.4 million in 2022, then jumped by 241.53% to $35.7 million in 2023, then decreased by 28.83% to $25.4 million in 2024, then decreased by 13.89% to $21.9 million in 2025, then increased by 0.35% to $21.9 million in 2026.
• The last three Research & Development figures came in at $21.9 million (Q1 2026), $21.9 million (Q4 2025), and $22.5 million (Q3 2025), per Business Quant data.